lyophilised powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-14 and is reviewed periodically as new material appears.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
Published studies are dominated by animal models of stroke, ischemia, and cognitive impairment, with a smaller number of human trials conducted in Russia. Many of the human reports are small, single-center, and published in Russian-language journals, which limits independent scrutiny. Outcome measures vary between studies and often rely on clinician-rated scales rather than objective biomarkers. Systematic reviews have noted the methodological weaknesses and called for larger, preregistered trials before firm conclusions can be drawn.
Claims about enhanced focus, memory, or mood in healthy people rest mostly on anecdotal reports and community discussion rather than on controlled data. It remains unclear whether any cognitive benefit observed in patients recovering from brain injury would extend to uninjured users. Dose-response relationships, long-term safety, and interactions with other drugs are not well characterized in the peer-reviewed literature. Questions about optimal route of administration and treatment duration likewise remain open.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Seven-residue peptide |
| Molecular mass | 813.9 Da | Monoisotopic value |
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Freely soluble in water | Also soluble in saline and polar solvents |
| Storage (dry) | -20 °C or lower | Desiccated, protected from light |
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
Common degradation pathways include oxidation of the methionine side chain, hydrolysis of the peptide backbone, and aggregation under unfavourable pH or concentration. Stability studies typically monitor the main peak by chromatography and report total related substances as a percentage. Because no official monograph exists, acceptance criteria vary between laboratories, and reported purity values are not directly comparable across suppliers. Analysts therefore document the method, column, and detection wavelength alongside each result, and open questions remain about how much biological activity the oxidised forms retain.
Solid semax is typically supplied as a lyophilised powder that is hygroscopic and sensitive to moisture, light, and repeated temperature cycling. Long-term storage of the dry peptide is generally recommended at approximately -20 degrees Celsius, while shorter working periods may use refrigeration at 2 to 8 degrees Celsius. Vials should remain tightly closed and desiccated when brought to room temperature, because condensation can damage the material before it is weighed. Dividing a batch into aliquots is preferable to thawing one container repeatedly.
Gender-affirming hormone therapy (GAHT), also known as hormone replacement therapy (HRT) or transgender hormone therapy, is a form of hormone therapy in which sex hormones and other hormonal medications are administered to transgender or gender nonconforming individuals for the purpose of more closely aligning their secondary sexual characteristics with their gender identity. This form of hormone therapy is given as one of two types, based on whether the goal of treatment is masculinization or feminization:
== Advisory roles and international engagement == Singh represented India on numerous national and international forestry bodies. He served as Chairman of the IX Commonwealth Forestry Conference in January 1968, where delegates recognized his effective moderation in revitalizing the conference's focus on global wood trends and economic forestry. His other international leadership roles included serving as Chairman of the Food and Agriculture Organization (FAO) Committee on Range Forest Management, Chairman of the Teak Sub-Commission, Chairman of the Technical Committee on Forestry and Forest Products (1965), and Vice-Chairman of the FAO Committee on Forest Development in the Tropics. He also participated in the Sixth World Forestry Congress in 1966. In 1970, following his retirement, the Government of India appointed him to the National Commission on Agriculture. Contributing heavily to the commission's 1976 report (Part IX on Forestry), Singh advocated for integrating forest management with agricultural objectives, emphasizing long-term ecological sustainability over the politically driven expansion of arable land.
Barry Halliwell, John MC Gutteridge. Free Radicals in Biology and Medicine (5th edn) (Oxford University Press, 2015) ISBN 0-19-871748-2 Barry Halliwell. Chloroplast Metabolism (2nd edn) (Oxford University Press, 1984) ISBN 0-19-854585-1 Reviews
Terry Peter Gallagher as Axel Zufo, a fossil fuels billionaire Billy Eichner as Waylen Lemming, a crypto billionaire David Pittu as Ronan Wylde, a banking billionaire Julie Halston as Kitty Munson, a multinational retail billionaire Matthew Laureano as Nate, a victim who is tortured and killed by the Assassin and Jeremy Rev Yolanda as Clara Gardner, a transgender scientist and Mike's best friend Lux Pascal as Clara after the transformation Laura Dreyfuss as Jennifer King Robert Harrington as Jefferson, Byron's bodyguard Kelli O'Hara as Juliana Williams, Meyer's wife Hazel Graye as Juliana after the transformation Kaylee Halko as Joey, the teenage daughter of Meyer and Juliana who has progeria Augusta Liv as Joey after the transformation Kevin Cahoon as Tiger "Tig" Forst, one of Byron and Franny's sons Ray Nicholson as Tig after the transformation Eric Petersen as Gunther Forst, one of Byron and Franny's sons Brandon Gillard as Gunther after the transformation Anthony Rapp as a Scientist who worked for the space colonization division of Byron's corporation Emma Halleen as Bella Grant, a school student who becomes fixated on the "Beauty" Annabelle Wachtel as Ruthie, Bella's best friend who is lamenting a failed nose job Paige McGarvin as Ruthie after the transformation Maria Dizzia as Marcy Grant, Bella's mother Daniel Stewart Sherman as Bella's father Carson Rowland as Conor, an employee of Byron's corporation who administers doses of the "Beauty" Ethan Eisenstein as Conor before the transformation Red Concepcion as Sir Ma'am, a social media influencer Sky Kawai as Sir Ma'am after the transformation
Sources: en.wikipedia.org
=== Pharmacokinetics === When administered together as dextromethorphan/bupropion, the elimination half-life of dextromethorphan is 22 hours and the elimination half-life of bupropion is 15 hours. The elimination half-lives of bupropion active metabolites are 35 hours for hydroxybupropion, 44 hours for erythrohydrobupropion, and 33 hours for threohydrobupropion. Bupropion inhibits the metabolism of dextromethorphan by inhibiting the enzyme CYP2D6, the major enzyme responsible for the metabolism of dextromethorphan. This in turn improves the bioavailability of dextromethorphan, prolongs its half-life, prevents its metabolism into dextrorphan, and increases the ratio of dextromethorphan to dextrorphan in the body.
By stimulating (or charging) genetically engineered roundworm mitochondria with light, researchers show that halting the decline in mitochondrial membrane potential can slow aging (30 Dec). Researchers report the development of 3D-printed flexible paper-thin organic photovoltaics. 12 December – Scientists describe a new method to break up so-called "forever chemicals" by infusing contaminated water with hydrogen, then blasting it with high-energy, short-wavelength ultraviolet light. 13 December The Newborn Genomes Programme is announced by the UK government. It will conduct whole genome sequencing of 100,000 newborns, the largest study of its kind in the world, to aid research into the diagnosis and treatment of rare genetic conditions. In a major milestone for the field, scientists at the National Ignition Facility report a net energy gain in the development of fusion power. COVID-19 pandemic: A study finds that the BQ and XBB subvariants of SARS-CoV-2 are "barely susceptible to neutralization" by vaccines, including the new Omicron boosters. Key antibody drugs, Evusheld and bebtelovimab, are "completely inactive" against the new subvariants. This could result in a surge of breakthrough infections and reinfections, according to the study team, although the vaccines hold up against severe disease. A study systematically assesses advice given by professional general practitioners, typically in the form of verbal-only consultation, for weight-loss to obese patients.
For copper, the CTAP-1 sensor shows a response in the UV region when Cu(I) binds to an azatetrathiacrown motif that in turn excites a pyrazoline-based dye that is attached. In Coppersensor-1 (CS1), a thioether-rich motif binds to Cu(I) causing the excitation of a boron-dipyrromethene (BODIPY) dye in the visible region. Iron sensors include Pryrene-TEMPO, in which the binding of iron to TEMPO quenches the fluorescence of pyrene when no Fe(II) is bound. Upon binding however, TEMPO is reduced and pyrene regains fluorescence. This probe is limited in that an analogous response can be generated by unwanted free radicals, and that it can only by used in acidic solution. The DansSQ Fe(II)-binding system consists of a Dansyl group bound to styrylquinoline and operates by the disruption of intra-molecular charge transfer. It is limited in that it is only soluble in acetonitrile in 10% H2O. Cobalt sensors have been made that capitalize on the breaking of C-O bonds by Co(II) in a fluorescent probe known as Cobalt Probe 1 (CP1).
Septoplasty is a corrective surgical procedure for nasal septum deviation in which the nasal septum is straightened. Tonsillectomy or adenoidectomy in an attempt to increase the size of the airway. Tonsillotomy Removal or reduction of parts of the soft palate and some or all of the uvula, such as uvulopalatopharyngoplasty (UPPP) or laser-assisted uvulopalatoplasty (LAUP). Modern variants of this procedure sometimes use radiofrequency waves to heat and remove tissue. Turbinectomy is a surgical procedure in which all or some of the turbinate bones are removed to relieve nasal obstruction. Reduction of the tongue base, either with laser excision or radiofrequency ablation. Genioglossus advancement, in which a small portion of the lower jaw that attaches to the tongue is moved forward, to pull the tongue away from the back of the airway. Hyoid suspension, in which the hyoid bone in the neck, another attachment point for tongue muscles, is pulled forward in front of the larynx. Maxillomandibular advancement Bariatric surgery (for morbid obesity) Hypoglossal nerve stimulation Radiofrequency ablation
Brincidofovir, sold under the brand name Tembexa, is an antiviral drug which was used to treat smallpox, prior to the global eradication of the disease in 1980. Brincidofovir is a prodrug of cidofovir. Conjugated to a lipid, the compound is designed to release cidofovir intracellularly, allowing for higher intracellular and lower plasma concentrations of cidofovir, effectively increasing its activity against dsDNA viruses, as well as oral bioavailability. The most common side effects include diarrhea, nausea, vomiting, and abdominal pain. It carries an FDA-mandated black box warning of an increased risk of death with extended use. Brincidofovir was approved for medical use in the United States in June 2021.
Sources: en.wikipedia.org
It is a synthetic peptide of seven amino acids. Its backbone corresponds to a fragment of adrenocorticotropic hormone extended at the carboxyl end. The material is distributed as a lyophilized solid for laboratory use.
The extension was introduced to slow enzymatic breakdown of the peptide in biological systems. Natural ACTH fragments are degraded rapidly by peptidases. Adding the tripeptide was intended to extend the window during which the molecule remains intact.
Most published work consists of animal experiments conducted in a small number of laboratories. Human data are limited in number and size. Whether the observed effects translate into reliable clinical benefit is still unresolved.
It is associated with the melanocortin receptor family, particularly subtypes found in the central nervous system. This interaction is separate from the adrenal pathway activated by full-length ACTH.